OnCall+ Alzheimer's Contributors

May 5, 2009 -- There are several research efforts related to Alzheimer's taking place at Mount Sinai. Highlights are detailed here:

- New imaging chemicals permit scientists to see Alzheimer's amyloid pathology on brain scans of living mice for the first time.

- Use of new transgenic mice and new imaging chemicals to screen for new Alzheimer's drugs that reduce amyloid buildup, including natural compounds from red wine (resveratrol) and drugs that improve how nerve cells communicate.

- New brain scans that evaluate brain function and aid in detecting and diagnosing the earliest stages of Alzheimer's.

- Clinical trials of the newest and most promising Alzheimer's drugs including amyloid vaccines and anti-amyloid drugs.

- Clinical trials and basic mechanisms of possible breakthrough drugs (e.g., Dimebon) in line for possible approval by the FDA.

OnCall+ Alzheimer's contributors from Mount Sinai include: Mary Sano, Ph.D. and Samuel Gandy, M.D., Ph.D.